Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study

Summary: Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial (NCT05223582) evaluates neoadjuvant fuzuloparib plus abiraterone in 35 treatment-naive men with localized high-risk pr...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Tingwei Zhang, Beihe Wang, Yu Wei, Hualei Gan, Bangwei Fang, Xiaomeng Li, Junlong Wu, Xiaojie Bian, Jianfei Wang, Stephen J. Freedland, Shenglin Huang, Dingwei Ye, Yao Zhu
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-03-01
Serija:	Cell Reports Medicine
Teme:	Prostate cancer neoadjuvant fuzuloparib abiraterone
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2666379125000916
Oznake:	Označite Brez oznak, prvi označite!